New Hampshire Trust Has $1.15 Million Holdings in Novartis AG $NVS

New Hampshire Trust grew its holdings in Novartis AG (NYSE:NVS) by 8.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,483 shares of the company’s stock after purchasing an additional 749 shares during the period. New Hampshire Trust’s holdings in Novartis were worth $1,148,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in shares of Novartis by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 8,606,724 shares of the company’s stock valued at $959,535,000 after purchasing an additional 422,869 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Novartis by 60.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,660,485 shares of the company’s stock worth $408,071,000 after acquiring an additional 1,377,252 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Novartis by 2.2% during the 1st quarter. Northern Trust Corp now owns 2,180,281 shares of the company’s stock worth $243,058,000 after acquiring an additional 47,690 shares during the last quarter. New Vernon Capital Holdings II LLC increased its holdings in shares of Novartis by 12,664.1% during the 1st quarter. New Vernon Capital Holdings II LLC now owns 1,383,244 shares of the company’s stock worth $154,204,000 after acquiring an additional 1,372,407 shares during the last quarter. Finally, Scharf Investments LLC increased its holdings in shares of Novartis by 0.3% during the 2nd quarter. Scharf Investments LLC now owns 1,262,444 shares of the company’s stock worth $152,770,000 after acquiring an additional 3,805 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Trading Down 0.9%

NVS opened at $130.48 on Friday. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55. The company has a 50-day simple moving average of $127.56 and a 200 day simple moving average of $119.49. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $275.64 billion, a price-to-earnings ratio of 18.99, a P/E/G ratio of 1.82 and a beta of 0.64.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wall Street Zen raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. The Goldman Sachs Group reissued a “sell” rating and set a $118.00 price target (down from $119.00) on shares of Novartis in a report on Friday, September 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. Morgan Stanley raised shares of Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target on the stock in a research report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Novartis has a consensus rating of “Hold” and an average target price of $120.33.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.